Regulation - North America, ThromboGenics

Filter

Popular Filters

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA

29-07-2012

Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

03-07-2012

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

ThromboGenics re-files ocriplasmin BLA and Inspiration submits IB 1001 to FDA

17-04-2012

Belgian biopharma company ThromboGenics NV (Euronext Brussels: THR) said this morning that it has resubmitted…

BiotechnologyInspiration BiopharmaceuticalsIpsenNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenics

Back to top